Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (10): 618-621.doi: 10.3760/cma.j.cn371439-20230428-00117

• Reviews • Previous Articles     Next Articles

Research progress of NADPH oxidase 2 in malignant tumors

Liu Xiaojie1,2, Huang Junxing1()   

  1. 1Department of Oncology, Affiliated Jiangsu Taizhou People's Hospital of Nanjing Medical University, Jiangsu Taizhou People's Hospital, Taizhou 225300, China
    2Department of Clinical Medicine, Dalian Medical University, Dalian 116000, China
  • Received:2023-04-28 Revised:2023-07-28 Online:2023-10-08 Published:2023-11-08
  • Contact: Huang Junxing E-mail:hjxtz@sina.cn
  • Supported by:
    Jiangsu Commission of Health Research Project(BJ20012);Jiangsu Provincial Medical Innovation Team Project(CXTDA2017042);Taizhou Science and Technology Support Plan(Social Development)Project(TS202001)

Abstract:

Reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (Nox2) acts as a source of reactive oxygen species, which participates in and influences normal physiological function of human body. Nowadays, many studies have found that Nox2 is related to prognosis of patients, drug resistance and molecular targeted therapy in various malignant tumors, such as acute myeloid leukemia, gastric cancer, colorectal cancer, ovarian cancer, lung cancer and esophageal cancer. What's more, it may be a novel biomarker and a potential therapeutic target for malignant tumors.

Key words: NADPH oxidase 2, Neoplasms, Reactive oxygen species, Drug resistance, neoplasm, Prognosis